Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report

摘要

Crizotinib, a multi-targeted MET/ALK/human c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor, is routinely used to treat patients with non-small-cell lung cancer with common ROS1 rearrangement. However, it remains unknown whether patients harboring rare ROS1 fusions can benefit from crizotinib treatment.